Antibiotic Sensitivity Patterns of Escherichia coli Isolated in Urine Samples of Patients Referred to Ayatollah Mousavi Hospital in Zanjan

Mojtaba Kamaliaghdam*, Mansour Sadeghzadeh*, Ahmad Jalilvand†, Kambiz Eftekhari‡, Zahra Rezaei§

1. Dept. of Pediatrics, Ayatollah Mousavi Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
2. Zanjan Metabolic Disease Research Center, Zanjan University of Medical Sciences, Zanjan, Iran
3. Dept. of Pathology, Ayatollah Mousavi Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
4. Dept. of Pediatrics, School of Medicine, Bahrami Hospital, Tehran University of Medical Sciences, Tehran, Iran
5. Pediatric Gastroenterology and Hepatology Research Center, Bahrami Hospital, Tehran University of Medical Sciences, Tehran, Iran

ABSTRACT

Background & Objective: Escherichia coli (E. coli) is considered to be the most common cause of urinary tract infections (UTIs) worldwide. Due to the recent rise in bacterial resistance to antibiotics and the appearance of multidrug-resistant E. coli, treatment options have been significantly limited, thus increasing the cost of treatment as well as morbidity and mortality rates, especially in developing countries. This study aimed to identify the antibiotic susceptibility patterns of E. coli for use in early empirical treatments and cultures of negative UTIs caused by previous antibiotic usage.

Materials & Methods: In the present study, 704 urine samples with a positive culture of E. coli were evaluated in terms of susceptibility to gentamicin, nitrofurantoin, cefazidime, cefixime, meropenem, cefepime, azithromycin, ceftriaxone and ciprofloxacin using the Kirby-Bauer disc diffusion method. Data were collected based on age, sex, and hospitalization or ambulatory patient status. Data were analyzed using SPSS 22.0.

Results: E. coli showed the lowest resistance to nitrofurantoin (4.5%) and the highest resistance to cefixime (34.9%). There was a statistically significant relationship between antibiotic resistance and age, gender, and hospitalization status.

Conclusion: Because of the high resistance rate of E. coli to cefixime, precautions should be taken before using cefixime to treat UTIs.

Keywords: Antibiotic sensitivity, Escherichia coli, Resistance, Urinary tract infections

Introduction

Escherichia coli (E. coli) is the most common organism causing urinary tract infections (UTIs) (1) and is the cause of about 90% of all UTIs in young women (2). UTIs are very common infectious diseases, both as community- and hospital-acquired infections (3,4). It is estimated that 10-20% of infections treated by primary care physicians and 30-40% of hospital-treated infections are due to UTIs (4). These infections are more prevalent in females and are found in about 40% of all females, with a 30% chance of relapse. UTIs are also more prevalent in the elderly than in younger people. The majority of UTI cases are mild (5), but they can lead to end-stage renal scarring, hypertension, and renal dysfunction, especially when the kidney is affected (6). The purpose of treating UTIs is to provide a quick cure and prevent complications. To achieve this goal in patients suspected of having a UTI, empirical treatment should be initiated before preparing the urine culture results (7,8). Due to the recent rise in bacterial resistance to antibiotics and the appearance of multidrug-resistant (MDR) E. coli, treatment options have been significantly limited; in developing countries, this situation may have a significant impact on treatment costs and increase the morbidity and mortality rates associated with UTIs (4,9). UTIs caused by resistant pathogens have a longer recovery period and higher relapse rates, and they mostly depend on various courses of antibiotic therapy (5). Thus, it is essential to be aware of the current antibiotic susceptibility patterns of E. coli (the main bacterial
cause of UTIs) in order to determine the most appropriate choice for empiric treatment (4). Antibiotic susceptibility patterns differ by location and time, so periodically testing antibiotic resistance in different hospitals, cities, and nations is crucial (2,5,10). Although many factors affect antibiotic resistance, the inappropriate and widespread use of antibiotics plays an important role (11). This study aimed to identify the antibiotic susceptibility pattern of E. coli in order to determine effective early empirical treatments and cultures for negative UTIs caused by previous antibiotic usage. By increasing the quality of treatment and decreasing the duration of treatment, we can reduce complications and reduce the cost of treatment.

Materials and Methods

In this study, we examined all urinary samples (24,706 cases) from inpatients and ambulatory patients referred to the laboratory of Ayatollah Mousavi Hospital in Zanjan between August 21, 2015, and August 21, 2016. Urine sampling was performed as a mid-stream urine clean catch in a sterile container. In children under three years old, samples were collected in a urine bag. The samples were immediately transferred to the laboratory and cultured in an agar plate. The culture plates were incubated at 37°C for 48 hours. Positive cultures were identified through standard biochemical methods. The isolation of a single type with colony counts of more than 10^5 colony-forming unit/mL was regarded as positive urine cultures. Positive cultures other than E. coli were discarded. There were a total of 704 E. coli positive samples for which antibiotic susceptibility to gentamicin, nitrofurantoin, ceftazidime, cefixime, meropenem, cefotaxime, cefepime, azithromycin, ceftriaxone, and ciprofloxacin, was examined using the Kirby-Bauer disc diffusion method. One isolate per patient was included in the study. Data were collected based on age, sex, and hospitalization or outpatient status. Values were expressed as numbers and percentages. Comparisons for categorical variables were performed via a Chi-square test. A P-value<0.05 was regarded as statistically significant. The data were analyzed using SPSS 22.0 (SPSS Inc., Chicago, IL, USA). This study was approved by the ethics committee of Zanjan University of Medical Sciences and has been registered with the code (zums.REC.1394.222).

Results

In this study, among 24,706 urine samples cultured in Ayatollah Mousavi Hospital Laboratory in Zanjan from August 21, 2015, to August 21, 2016, 704 E. coli positive urine samples were isolated. Of these isolates, 188 (26.7%) were derived from males, and 516 (73.3%) were derived from females. There were 216 (30.7%) inpatient samples and 488 (69.3%) from ambulatory settings. In terms of age distribution, 24 (3.4%) were under one month, 86 (12.2%) were 1-12 months, 68 (9.7%) were 1-5 years, 68 (9.7%) were 5-10 years, 30 (4.3%) were 10-18 years, 216 (30.7%) were 18-40 years, 132 (18.8%) were 40-65 years, and 80 (11.4%) were over 65 years old.

The sensitivities of isolated E. coli to common antibiotics are shown in Table 1, and their differences by gender are shown in Table 2. These findings showed that for all antibiotics, E. coli is more resistant in men than in women (P=0.00).

Based on the results of this study, E. coli samples obtained from hospitalized patients showed a higher rate of resistance than outpatients (P=0/00) (Table 3).

Antibiotic susceptibility findings of the E. coli isolated from urine samples of UTI patients by age are shown in Table 4.

Table 1. The sensitivity of the isolated E. coli from patients’ urine samples

| Antibiotics       | Number of isolates (percent) |
|-------------------|-----------------------------|
|                   | resistant | intermediate | sensitive |
| Meropenem         | 50(7.1)   | 10(1.4)       | 644(91.5) |
| Ceftazidime       | 102(14.5) | 34(4.8)       | 568(80.7) |
| Cefepime          | 96(13.6)  | 40(5.7)       | 568(80.7) |
| Azithromycin      | 176(25)   | 20(2.8)       | 508(72.2) |
| Gentamicin        | 114(16.2) | 18(2.6)       | 572(81.2) |
| Ceftriaxone       | 212(30.2) | 20(2.8)       | 472(67)   |
| Ciprofloxacin     | 180(25.5) | 4(0.6)        | 520(73.9) |
| Cefixime          | 246(34.9) | 18(2.6)       | 440(62.5) |
| Nitrofurantoin    | 32(4.5)   | 8(1.2)        | 664(94.3) |
Table 2. The sensitivity of the isolated *E. coli* from patients’ urine samples by gender

| Antibiotics      | Gender | Number of isolates (percent) | P-value |
|------------------|--------|-----------------------------|---------|
|                  |        | resistant | intermediate | sensitive |         |
| Meropenem        | male   | 36(19.1) | 4(2.1)       | 148(78.8) | 0.001<  |
|                  | female | 14(2.7)  | 6(1.2)       | 496(96.1) |         |
| Ceftazidime      | male   | 62(33)   | 16(8.5)      | 110(58.5) | 0.001   |
|                  | female | 40(7.8)  | 18(3.5)      | 458(88.8) |         |
| Cefepime         | male   | 62(33)   | 20(10.6)     | 106(56.4) | 0.001   |
|                  | female | 34(6.6)  | 20(3.9)      | 462(89.5) |         |
| Azithromycin     | male   | 64(34)   | 4(2.1)       | 120(63.8) | 0.08    |
|                  | female | 112(21.7)| 16(3.1)      | 388(75.2) |         |
| Gentamicin       | male   | 60(31.9) | 10(5.3)      | 118(62.8) | 0.001<  |
|                  | female | 54(10.5)| 8(3)         | 454(88)   |         |
| Cefepime         | male   | 98(52.1) | 4(2.1)       | 86(45.8)  |         |
|                  | female | 114(22.1)| 16(3.1)      | 368(74.8) |         |
| Azithromycin     | male   | 82(43.6) | -             | 106(56.4) |         |
|                  | female | 98(19)   | 4(0.8)       | 414(80.2) |         |
| Cefepime         | male   | 102(54.3)| 4(2.1)       | 82(43.6)  |         |
|                  | female | 144(27.9)| 14(2.7)      | 358(69.4) |         |
| Nitrofurantoin   | male   | 26(13.8) | 2(1.1)       | 160(85.1) | 0.001<  |
|                  | female | 6(1.2)   | 6(1.2)       | 504(97.6) |         |

Table 3. The sensitivity of the isolated *E. coli* from patients’ urine samples by Hospitalization status

| Antibiotics      | Hospitalization status | Number of isolates (percent) | P-value |
|------------------|------------------------|-----------------------------|---------|
|                  |                        | resistant | intermediate | sensitive |         |
| Meropenem        | inpatient              | 24(11.1) | 4(1.9)       | 188(87)   | <0.001  |
|                  | outpatient             | 26(5.3)  | 6(1.2)       | 546(93.4) |         |
| Ceftazidime      | inpatient              | 54(25)   | 16(7.4)      | 146(67.6) | <0.001  |
|                  | outpatient             | 48(9.8)  | 18(3.7)      | 422(86.5) |         |
| Cefepime         | inpatient              | 62(28.7) | 12(5.6)      | 142(65.7) | <0.001  |
|                  | outpatient             | 34(7)    | 28(5.7)      | 426(87.3) |         |
| Azithromycin     | inpatient              | 80(37)   | 2(0.9)       | 134(62)   | <0.001  |
|                  | outpatient             | 96(1907) | 18(3.7)      | 372(76.2) |         |
| Gentamicin       | inpatient              | 58(26.9) | 8(3.7)       | 150(69.4) | <0.001  |
|                  | outpatient             | 56(11.5) | 10(2)        | 422(86.5) |         |
| Ceftriaxone      | inpatient              | 106(49.1)| 4(1.8)       | 106(49.1) | <0.001  |
|                  | outpatient             | 106(21.7)| 16(3.3)      | 366(75)   |         |
| Ciprofloxacin    | inpatient              | 90(41.7) | -             | 126(58.3) | <0.001  |
|                  | outpatient             | 90(18.5) | 4(0.8)       | 394(80.7) |         |
| Cefixime         | inpatient              | 116(53.7)| 2(0.9)       | 98(45.4)  | <0.001  |
|                  | outpatient             | 130(26.6)| 16(3.3)      | 342(70.1) |         |
| Nitrofurantoin   | inpatient              | 28(13)   | 2(0.9)       | 186(86.1) | <0.001  |
|                  | outpatient             | 4(0.8)   | 6(1.2)       | 478(98)   |         |
| Antibiotics | Age          | Number of isolates (percent) | P-value |
|-------------|--------------|------------------------------|---------|
|             |              | resistant | intermediate | sensitive |         |
| Meropenem   | <1 month     | 2(8.3)    | -             | 22(91.7)  | 0.03    |
|             | 1-12 months  | 14(16.3)  | -             | 72(83.7)  |         |
|             | 5-1 years    | 2(2.9)    | -             | 66(97.1)  |         |
|             | 10-5 years   | 4(5.9)    | 2(2.9)        | 62(91.2)  |         |
|             | 18-10 years  | 2(6.7)    | -             | 28(93.3)  |         |
|             | 40-18 years  | 10(4.6)   | 6(2.8)        | 200(92.6) |         |
|             | 65-40 years  | 8(6.1)    | -             | 70(93.9)  |         |
|             | ≤65 years    | 8(10)     | 2(2.5)        | 70(87.5)  |         |
| Ceftazidime | <1 month     | 20(23.3)  | 2(2.3)        | 64(74.4)  | <0.001  |
|             | 5-1 years    | 4(5.9)    | 6(8.8)        | 58(85.3)  |         |
|             | 10-5 years   | 8(11.8)   | 2(2.9)        | 58(85.3)  |         |
|             | 18-10 years  | 6(20)     | -             | 24(80)    |         |
|             | 40-18 years  | 20(9.3)   | 6(2.7)        | 190(88)   |         |
|             | 65-40 years  | 14(10.6)  | 10(7.6)       | 108(81.8) |         |
|             | ≤65 years    | 26(32.5)  | 8(10)         | 46(57.5)  |         |
|             | <1 month     | 4(6.7)    | -             | 20(83.3)  |         |
|             | 1-12 months  | 22(25.6)  | 2(2.3)        | 62(72.1)  |         |
|             | 5-1 years    | 4(5.9)    | 8(11.8)       | 56(82.4)  | <0.001  |
|             | 10-5 years   | 12(17.6)  | -             | 56(82.4)  |         |
|             | 18-10 years  | 2(6.7)    | 2(6.7)        | 26(86.7)  |         |
|             | 40-18 years  | 18(8.3)   | 4(1.9)        | 194(89.8) |         |
|             | 65-40 years  | 12(9.1)   | 16(12.1)      | 104(78.8) |         |
|             | ≤65 years    | 22(27.5)  | 8(10)         | 50(62.5)  |         |
|             | <1 month     | 4(16.7)   | -             | 20(83.3)  |         |
|             | 1-12 months  | 32(37.2)  | 4(4.7)        | 50(58.1)  |         |
|             | 5-1 years    | 14(20.6)  | 2(2.9)        | 50(73.5)  |         |
|             | 10-5 years   | 16(32.5)  | 2(2.9)        | 50(73.5)  |         |
|             | 18-10 years  | 8(26.7)   | 2(6.7)        | 20(66.7)  | 0.016   |
|             | 40-18 years  | 48(22.2)  | 6(2.8)        | 162(75)   |         |
|             | 65-40 years  | 40(30.3)  | 2(2.5)        | 90(68.2)  |         |
|             | ≤65 years    | 14(17.5)  | 2(2.5)        | 64(80)    |         |
|             | <1 month     | 4(6.7)    | -             | 20(83.3)  |         |
| Azithromycin| 1-12 months  | 18(20.9)  | 2(2.3)        | 66(76.8)  |         |
|             | 5-1 years    | 14(20.6)  | -             | 54(79.4)  |         |
|             | 10-5 years   | 8(11.8)   | -             | 60(88.2)  |         |
|             | 18-10 years  | 8(26.7)   | -             | 22(73.3)  | 0.032   |
| Gentamicin  | <1 month     | 20(83.3)  | -             | 4(16.7)   |         |
|             | 1-12 months  | 66(76.8)  | -             | 20(23.2)  |         |
|             | 5-1 years    | 62(72.1)  | -             | 22(27.5)  |         |
|             | 10-5 years   | 28(93.3)  | -             | 2(6.7)    |         |
|             | 18-10 years  | 10(4.6)   | 6(2.8)        | 162(75)   |         |
|             | 65-40 years  | 40(30.3)  | 2(2.5)        | 90(68.2)  |         |
| Antibiotics | Age                  | Number of isolates (percent) | P-value |
|------------|----------------------|------------------------------|---------|
|            |                      | resistant | intermediate | sensitive |         |
|            | 40-18 years          | 26(12)    | 4(1.9)       | 186(86.1) |         |
|            | 65-40 years          | 20(15.2)  | 6(4.5)       | 106(80.3) |         |
|            | ≤65 years            | 16(20)    | 6(7.5)       | 58(72.5)  |         |
|            | <1 month             | 4(16.7)   | -            | 20(83.3)  | <0.001  |
|            | 1-12 months          | 34(39.5)  | 4(4.7)       | 48(55.8)  |         |
|            | 5-1 years            | 14(20.6)  | 2(2.9)       | 52(76.5)  |         |
|            | 10-5 years           | 10(14.7)  | 4(5.9)       | 54(79.4)  |         |
|            | 18-10 years          | (26.7)    | 2(6.7)       | 20(66.7)  |         |
| Ceftriaxone | 40-18 years          | 48(22.2)  | 6(2.8)       | 162(75)   |         |
|            | 65-40 years          | 52(39.4)  | 2(1.5)       | 78(59.1)  |         |
|            | ≤65 years            | 42(52.5)  | -            | 38(47.5)  |         |
|            | <1 month             | 4(16.7)   | -            | 20(83.3)  |         |
|            | 1-12 months          | 32(37.2)  | -            | 54(62.8)  |         |
|            | 5-1 years            | 12(17.6)  | 2(2.9)       | 54(79.5)  |         |
|            | 10-5 years           | 8(11.8)   | -            | 60(88.2)  | <0.001  |
|            | 18-10 years          | 6(20)     | -            | 24(80)    |         |
|            | 40-18 years          | 36(16.7)  | 2(0.9)       | 178(82.4) |         |
| Ciprofloxacine | 65-40 years          | 46(34.8)  | -            | 86(65.2)  |         |
|            | ≤65 years            | 36(45)    | -            | 44(55)    |         |
|            | <1 month             | 4(16.7)   | -            | 20(83.3)  |         |
|            | 1-12 months          | 48(55.8)  | -            | 38(44.2)  |         |
|            | 5-1 years            | 18(26.5)  | 2(2.9)       | 48(70.6)  | <0.001  |
|            | 10-5 years           | 16(23.5)  | 4(5.9)       | 48(70.6)  |         |
|            | 18-10 years          | 10(33.3)  | -            | 20(66.7)  |         |
|            | 40-18 years          | 58(26.9)  | 2(2.9)       | 156(70.2) |         |
|            | 65-40 years          | 50(37.9)  | 10(7.6)      | 72(54.5)  |         |
|            | ≤65 years            | 42(52.5)  | -            | 38(47.5)  |         |
|            | <1 month             | 2(8.3)    | -            | 22(91.7)  |         |
|            | 1-12 months          | 4(4.7)    | 2(2.3)       | 80(93)    |         |
| Cefixime   | 5-1 years            | 2(2.9)    | -            | 66(97.1)  |         |
|            | 10-5 years           | 2(2.9)    | 2(2.9)       | 64(94.1)  |         |
|            | 18-10 years          | 2(6.7)    | -            | 28(93.3)  |         |
|            | 40-18 years          | 8(3.7)    | 4(1.9)       | 20(94.4)  |         |
|            | 65-40 years          | 6(4.5)    | -            | 126(95.5) |         |
|            | ≤65 years            | 6(7.5)    | -            | 74(92.5)  |         |
| Nitrofurantoin | 1-12 months          | 2(2.9)    | -            | 66(97.1)  |         |
|            | 5-1 years            | 2(2.9)    | 2(2.9)       | 64(94.1)  |         |
|            | 10-5 years           | 2(6.7)    | -            | 28(93.3)  |         |
|            | 18-10 years          | 8(3.7)    | 4(1.9)       | 20(94.4)  |         |
|            | 40-18 years          | 6(4.5)    | -            | 126(95.5) |         |
|            | ≤65 years            | 6(7.5)    | -            | 74(92.5)  |         |
Discussion

Our study showed that the antibiotic resistance of E. coli isolates varied from 4.5% to nearly 35% with different antibiotics (12-15).

Kullkarni et al. examined 1,000 urine samples of patients suspected of having a UTI. Of these, 395 had positive E. coli cultures, 170 (43%) of which showed MDR. The resistance rates against ampicillin and ceftriaxone were 82.53% and 66.58%, respectively. However, the sensitivity to imipenem was 96.71%, and sensitivity to nitrofurantoin was 92.41% (16).

In a five-year study on the first UTI with positive E. coli culture, Fasugba found that the highest antibiotic resistance rates were found for ampicillin (41.9%) and co-trimoxazole (20.7%). The lowest antibiotic resistance rates were reported for meropenem (0.0%) and nitrofurantoin (2.9%) (17).

Dehbani Pour et al. examined E. coli in Esfahan; it showed high resistance to ceftriaxone (13). In another study by Ferdowsi et al. in Babol in 2013, E. coli resistance to cefixime and ceftriaxone was reported to be ≥ 35.1%, which is consistent with the results of the current study (18). Overall, these data indicate that resistance to nitrofurantoin is low among E. coli isolates. There are several factors involved in preventing E. coli resistance to nitrofurantoin. Of course, nitrofurantoin is not widely used because of its unpleasant taste and inefficiency in pyelonephritis due to its low tissue penetration.

Sanchez GV et al. conducted a population-based study from 2000 to 2010 in the United States to investigate the in vitro antimicrobial resistance of urine E. coli isolates. They found that resistance to nitrofurantoin increased from 0.8% to 1.6% over this time. However, the resistance level for ciprofloxacin increased from 3% to 17.1% (19). In 2012, Kahlmeter G. et al. showed a low rate of resistance to nitrofurantoin, while the resistance during 2007-2008 was ≤ 2% (15). In the present study, E. coli exhibited the greatest resistance to cefixime, supporting the findings of Mirsoleymani et al. in Bandar Abbas, Iran, from 2009-2012 (12). Our study showed that for all antibiotics, E. coli resistance in men was greater than in women. This is similar to the results presented by Rossana Rosa, Alot, and Gupta (14,20,21). In general, all cases of UTI are considered to be complicated in men, especially when they occur in infants and children or in association with neurological disorders such as bladder outlet obstruction (prostatic hyperplasia) or urinary tract manipulation. However, uncomplicated UTIs also occur in a small number of men between the ages of 15-50 years. (22) We also studied the sensitivity of E. coli to antibiotics in terms of hospitalization and outpatient. Our results revealed that urine isolated E. coli from hospitalized patients showed greater resistance to all antibiotics when compared to ambulatory patients. This difference was statistically significant (P=0.00). Debanipour also reported higher overall antibiotic resistance and multidrug resistance in hospitalized patients than in ambulatory patients (13). Hospital pathogens typically show greater resistance than community-acquired pathogens (13). Of course, for a variety of reasons, hospitalized patients have poorer immune systems than ambulatory patients, and the underlying factor that leads to hospitalization may also be added to the resistance problem. Regarding the pattern of antibiotic resistance based on age group, the findings of this study showed that antibiotic resistance is higher in the newborn infants and patients over 65 years old than in other age groups. This may be due to comorbidities in elderly people and the weakened immune systems of these individuals. On the other hand, hospitalization rates in infants and the elderly are higher than other age groups, which, as mentioned, can increase the rate of antibiotic resistance (23). Our results showed that—except in the age group below one month and above 65 years, for which UTIs were more prevalent in males—the majority of cases were females. This is similar to the results presented by Debanipour (13) but different from those provided by Mirsoleymani, who found that UTIs were more common in males than females (12). This discrepancy may be due to differences in the populations that comprised the study groups. In our study, all age groups were included, whereas only pediatric populations were evaluated by Mirsoleymani (12).

Conclusion

In this study, as predicted, the highest prevalence of E. coli infection was observed in the age group of 18-40 years, especially in women. Due to sexual activity and the anatomy of the genital tract, women in this age group are susceptible to UTIs. Considering the high resistance of E. coli to UTIs, this study suggests that these drugs are not appropriate antibiotics for UTI therapy, possibly due to the overuse of these antibiotics in recent years.

Therefore, it is suggested that cefixime should be used more cautiously for empiric therapy in cystitis. For treating severe cases of pyelonephritis, dual-agent therapy (ceftazidime or cefepime with an aminoglycoside), or carbapenem alone, is recommended. This study also emphasized the importance of the appropriate use of antibiotics, especially cefixime and ceftriaxone, in avoiding further increases in antibiotic resistance.

Acknowledgments

This project was a thesis for a medical degree and was founded by the Research Department of Zanjan University of Medical Sciences. The authors greatly appreciate for the generous cooperation of the laboratory staff of Ayatollah Mousavi Hospital in Zanjan.
Conflict of Interest

Authors declared no conflict of interest.

References

1. Matthews SJ, Lancaster JW. Urinary tract infections in the elderly population. Am J Geriatric Pharmacother. 2011; 9 (5): 286-309. [DOI:10.1016/j.amjpharm.2011.07.002]

2. Raeespour M, Ranjarb R. Antibiotic resistance, virulence factors and genotyping of Uropathogenic Escherichia coli strains. Antimicrob Resist Infect Control. 2018;7:118. [DOI:10.1186/s13756-018-0411-4]

3. Odongo I, Ssemambo R, Kungu JM. Prevalence of Escherichia Coli and its antimicrobial susceptibility profiles among patients with UTI at Mulago Hospital, Kampala, Uganda. interdiscip Perspect Infect Dis. 2020;2020:8042540. doi: 10.1155/2020/8042540. eCollection 2020. [DOI:10.1155/2020/8042540]

4. Stefanik E, Suchocka U, Bosacka K, Hryniewicz W. Etiology and antibiotic susceptibility of bacterial pathogens responsible for community-acquired urinary tract infections in Poland. Eur J Clin Microbiol Infect Dis. 2016;35(8):1363-9. doi: 10.1007/s10096-016-2673-1. [DOI:10.1007/s10096-016-2673-1]

5. Yekani M, Baghi HB, Sefidan FY, Azargun R, Memar MY, Ghotaslou R. The rates of quinolone, trimethoprim/sulfamethoxazole and aminoglycoside resistance among Enterobacteriaceae isolated from urinary tract infections in a tertiary hospital of north eastern Karnataka, India. J Med Microbiol. 2014;63:7091-7095. [DOI:10.1093/jac/dkt271]

6. Conover MS, Hibbing ME, Hultgren S. Introduction to urinary tract infections. Metabolism of Human Diseases: Organ Physiology and Pathophysiology. 2014: 357. [DOI:10.1007/978-3-7091-0715-7_32]

7. Al Benwan K, Al Sweih N, Rotimi VO. Etiology and antibiotic susceptibility patterns of community- and hospital-acquired urinary tract infections in a general hospital in Kuwait. Med Prin Pract. 2010; 19 (6): 440-6. [DOI:10.1159/000320301]

8. Dibua UM, Onyemereha IS, Nweze EI. Frequency, urinalysis and susceptibility profile of pathogens causing urinary tract infections in Enugu State, southeast Nigeria. Magazine do Instituto de Medicina Tropical de São Paulo. 2014; 56 (1): 55-9. [DOI:10.1590/S0036-46652014000100008]

9. Niranjan V, Malini A. Antimicrobial resistance pattern in Escherichia coli causing urinary tract infection among inpatients. Indian J Med Res. 2014;139(6):945-8.

10. Sudheendra Ramesh Kulkarni, Basavaraj V, Peerpur, Kumar Sai Sailesh. Isolation and antibiotic susceptibility pattern of Escherichia coli from urinary tract infections in a tertiary care hospital of north eastern Karnataka.J Nat Sci Biol Med. 2017; 8(2): 176-180. doi: 10.4103/0976-9668.210012 [DOI:10.4103/0976-9668.210012]

11. Kiffer CR, Mendes C, Oplustil CP, Sampaio JL. Antibiotic resistance and trend of urinary pathogens in general outpatients from a major urban city. Int Brazil J Urol. 2007; 33 (1): 42-9. [DOI:10.1590/S1677-55382007000100007]

12. Mirsoleymani SR, Salimi M, Shareghi Brojeni M, Ranjarb M, Mehtarpoor M. Bacterial pathogens and antimicrobial resistance patterns in pediatric urinary tract infections: a four-year surveillance study (2009-2012). Int J Pediatr. 2014; Article ID 126142. https://doi.org/10.1155/2014/126142 [DOI:10.1155/2014/126142]

13. Dehbanipur R, Rastaghi S, Sedighi M, Maleki N, Faghi H. High prevalence of multidrug-resistance uropathogenic Escherichia coli strains, Isfahan, Iran. J Natural Sci, Biol, and Med. 2016; 7 (1): 22. [DOI:10.4103/0976-9668.175020]

14. Gupta K, Hooton TM, Stamm WE. Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis. J Antimicrob Chemother. 2005; 56 (1): 243-6. [DOI:10.1093/jac/dki169]

15. Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO • SENS study revisited. Int J Antimicrob Agents. 2012; 39 (1): 45-51. [DOI:10.1016/j.ijantimicag.2011.09.013]

16. Kulkarni SR, Peerpur BV, Sailesh KS. Isolation and antibiotic susceptibility pattern of Escherichia coli from urinary tract infections in a tertiary care hospital of North Eastern Karnataka. J Nat Sci Biol Med. 2017;8(2):176-180. doi: 10.4103/0976-9668.210012. [DOI:10.4103/0976-9668.210012]

17. Fasugba O, Mitchell BG, Mzatzzanagi an G, Das A, Colllignon P, Gardner A. Five-year antimicrobial resistance patterns of urinary Escherichia Coli at an Australian Tertiary Hospital: Time series analyses of prevalence data. PLoS ONE. 2016; 11(10):e0164306.doi:10.1371/journal.pone.0164306. [DOI:10.1371/journal.pone.0164306]

18. Ferdosi-Shahandashti E, Javanian M, Moradian-Kouchaksaraei M, et al. Resistance patterns of Escherichia coli causing urinary tract infection. Caspian J Inter Med. 2015; 6 (3): 148.

19. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary E
coli among US outpatients from 2000 to 2010. Antimicrob Agent Chemother. 2012;56(4):2181-3. [DOI:10.1128/AAC.06060-11]

20. Alos JI, Serrano MG, Gomez Garces JL, Perianes J. Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data. Clin J Microbiol Infect. 2005;11(3): 199-203. DOI: 10.1111/j.1469-0691.2004.01057.x [DOI:10.1111/j.1469-0691.2004.01057.x]

21. Rosa R, Abbo LM, Raney K, Tookes HE 3rd, Supino M. Antimicrobial resistance in urinary tract infections at a large urban emergency department: Contributing factors to empirical treatment failure. Am J Emerg Med. 2017;35(3):397-401. doi: 10.1016/j.ajem.2016.11.021. Epub 2016 Nov 9 [DOI:10.1016/j.ajem.2016.11.021]

22. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and burden disease. Infect Dis Clin North Am. 2014; 28 (1): 1-13. [DOI:10.1016/j.idc.2013.09.003]

23. Spoorenberg V, Prins J, Stobberingh E, Hulscher M, Geerlings S. Adequacy of an evidence-based guideline treatment for complicated urinary tract infections in the Netherlands and the effectiveness of guideline adherence. Europ J Clin Microbiol & Infect Dis. 2013; 32 (12): 1545-56 [DOI:10.1007/s10096-013-1909-6]

How to Cite This Article:

Kamali adaghm M, Sadeghzadeh M, Jalilvand A, Eftekhari K, Rezaei Z. Antibiotic Sensitivity Patterns of Escherichia coli Isolated in Urine Samples of Patients Referred to Ayatollah Mousavi Hospital in Zanjan. J Adv Med Biomed Res. 2020; 28 (128): 124-131

Download citation: BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks

Send citation to: Mendeley | Zotero | RefWorks